Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma
This study has been completed.
Asan Medical Center
Information provided by (Responsible Party):
Cheolwon Suh, Asan Medical Center
First received: June 13, 2006
Last updated: February 13, 2016
Last verified: February 2016
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||May 2010|
|Primary Completion Date:||February 2009 (Final data collection date for primary outcome measure)|
Kang BW, Kim WS, Kim C, Jang G, Lee SS, Choi YH, Lee DH, Kim SW, Kim S, Ryu JS, Huh J, Lee JS, Suh C. Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Invest New Drugs. 2010 Aug;28(4):516-22. doi: 10.1007/s10637-009-9283-z. Epub 2009 Jun 23.